.png){kind=icon}
返回
M
Margarita Majem
Autonomous University of Barcelona
55H指数
535论文数
2.4W被引数
收录论文 120
发表时间
.png){kind=icon}
Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies非小细胞肺癌患者皮下和静脉注射阿替利珠单抗的疗效与安全性，包括早期、局部晚期或转移性疾病：IMscin001和IMscin002随机研究的更新结果.png)
Lung Cancer.png)
OAAI
Lung CancerIF4.4
OAAI.png){kind=icon}
分享.png){kind=icon}
收藏Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial)基线时循环免疫细胞中PD-L1的表达作为接受度鲁鲁单抗联合卡铂-足叶乙苷治疗广泛期小细胞肺癌患者生存和免疫相关不良事件的预测因子（NCT04712903试验）OAAI
OAAI分享收藏Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology癌症患者靶向治疗、抗体-药物偶联物和免疫治疗的皮肤不良反应的诊断和治疗: 西班牙肿瘤内科学会和西班牙皮肤病与性病学学会的全国共识声明
OAAI
OAAI分享收藏Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC患者报告结局和症状进展时间来自PAPILLON研究：amivantamab联合化疗对比化疗作为表皮生长因子受体（EGFR）外显子20插入突变型晚期非小细胞肺癌的一线治疗Lung Cancer
Lung CancerIF4.4
PREAI
分享收藏